• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Wien Klin Wochenschr . 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort

tetano

Editor, Senior Moderator
Wien Klin Wochenschr


. 2020 Dec 9.
doi: 10.1007/s00508-020-01795-7. Online ahead of print.
6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort


Florian Deisenhammer[SUP] 1 [/SUP], Wegene Borena[SUP] 2 [/SUP], Angelika Bauer[SUP] 3 [/SUP], Janine Kimpel[SUP] 2 [/SUP], Dagmar Rudzki[SUP] 3 [/SUP], Kathrin Schanda[SUP] 3 [/SUP], Jonas Egeter[SUP] 4 [/SUP], Katharina H?fner[SUP] 4 [/SUP], Barbara Sperner-Unterweger[SUP] 4 [/SUP], Markus Reindl[SUP] 3 [/SUP]



Affiliations

Abstract

Background: As coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 evolved only recently, the persistency of the anti-viral antibody response remains to be determined.
Methods: We prospectively followed 29 coronavirus disease 2019 cases, mean age 44 ? 13.2 years. Except for one participant with a pre-existing diagnosis of rheumatoid arthritis, all other participants were previously healthy. We determined anti-viral binding antibodies at 2-10 weeks, 3 months, and 6 months after disease onset as well as neutralizing antibodies at 6 months. Two binding antibody assays were used, targeting the S1 subunit of the spike protein, and the receptor binding domain.
Results: All participants fully recovered spontaneously except for one who had persisting hyposmia. Antibodies to the receptor binding domain persisted for 6 months in all cases with a slight increase of titers, whereas antibodies to S1 dropped below the cut-off point in 2 participants and showed a minimal decrease on average, mainly at month 3 of follow-up in males; however, neutralizing antibodies were detected in all samples at 6 months of follow-up.
Conclusion: There is a stable and persisting antibody response against acute respiratory syndrome coronavirus 2 at 6 months after infection. Neutralizing antibodies confirm virus specificity. As the number of coronavirus disease 2019 convalescent cases is increasing sharply, antibody testing should be implemented to identify immunized individuals. This information can be helpful in various settings of professional and private life.

Keywords: ELISA; Immunity; Neutralizing; Prospective; Virus.
 
Back
Top Bottom